bioAffinity Awarded New Patent; Company’s Patent Portfolio Continues to Expand
SAN ANTONIO, Texas, Aug. 24, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of patient response to cancer therapy.
The U.S. Patent, entitled “5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) and Kit for Use with Detecting Cancer,” relates to the use of the porphyrin-based CyPath® assay for the early detection of dysplastic, pre-cancerous and cancerous cells from tissue samples both in vitro and in situ. CyPath® preferentially binds to cancer cells, giving them a distinctive fluorescence that can be used to detect cancer at an early stage of the disease by an imaging system.
“The newly awarded patent expands our intellectual property estate and provides important protection as we move toward commercialization of our lung cancer assay,” bioAffinity President and CEO Maria Zannes said. “bioAffinity’s current research on the CyPath® diagnostic and our porphyrin-conjugated chemotherapeutic agents for the delivery of drug therapies is reaching beyond product development to provide greater understanding of the fundamental nature of cancer. We are laying the foundation for a game-changing entry into the cancer diagnosis and treatment markets.”
bioAffinity’s patent portfolio includes 42 awarded patents in 21 countries and six patents pending. U.S. Patent 9,417,241 expands on earlier patents for the detection of precancerous, or dysplastic, cells and cancerous cells based on their unique propensity to take up the bioAffinity assay significantly more than healthy cells.
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers. CyPath® Lung, bioAffinity’s initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Contact: Maria Zannes, 505.400.9747
Released August 24, 2016